The firm worked with SV Health Investors, Sanofi Ventures and Abingworth
Johnson Winter Slattery (JWS) has assisted three of the lead investors in AdvanCell’s US$112m Series C financing effort.
The firm worked with SV Health Investors, Sanofi Ventures and Abingworth on the financing process, including transaction structuring, due diligence, negotiation, and the preparation of all transaction documents. JWS collaborated with the US-based Honigman team.
SV Health Investors’ Jamil M. Beg will join the AdvanCell board of directors, as will Sanofi Ventures’ Christopher Gagliardi and Abingworth’s Bali Muralidhar.
The funding round is expected to support the expansion of AdvanCell’s manufacturing capacity and speed up the clinical development of radionuclide therapies pipeline, according to Business Wire. The fourth lead investor is SymBiosis; current investor Morningside and new investors including Tenmile and Brandon Capital contributed as well.
“The financing is a significant milestone for AdvanCell and we look forward to seeing the company continue its journey to transform cancer care”, JWS lead partner Clare Brown said.
Brown received support from senior associate Nick Haenel and associates James Antonenas, Joshua Chin and Gabriele Santoro.
